Skip to content
  • Research

Island Pharmaceuticals (ASX:ILA)
Regulatory Alignment and Strategic Partnerships Accelerate Galidesivir Toward Animal Rule Approval

05 Mar 2026 – ILA Research Update – Pathway Confirmed and USAMRIID and the Geneva Foundation Collaboration

© 2026 Prenzler Group - All Rights Reserved. 

Prenzler Group Pty Ltd (ABN 77 621 100 730) is a corporate Authorised Representative (1257636) of BR Securities Australia Pty Ltd (ABN 92 168 734 530), the holder of Australian Financial Services Licence number 456663. The information contained in this website is only intended for the use of those persons who satisfy the Wholesale definition, pursuant to Section 761G and Section 761GA of the Corporations Act 2001 (Cth) (“the Act”). Persons accessing this information should consider whether they are wholesale clients in accordance with the Act before relying on any information contained. Any advice provided is general in nature.

Prenzler Group FSG

Privacy Policy

Disclaimers

Access Institutional Research

Please enter your details below to continue reading research from the Prenzler Group Analyst Team

This research is intended only for investors who qualify as “sophisticated” or “professional” under section 708 of the Corporations Act. It does not take into account your objectives, financial situation or needs.

You consent to receiving future research updates. Unsubscribe anytime.

Are you an s708 investor?

Select an Option